IQVIA艾昆纬：2025年返佣模式将如何影响340B药品定价计划中的现金流？（英文版）

On October 30, 2025, the Health Resources and Services Administration (HRSA) approved plans for eight manufacturers to participate in a rebate pilot for the 340B Drug Pricing Program (“340B Program”), signaling a shift from upfront discounts to retrospective rebates. Rebate critics assert that rebates will be a severe financial burden on providers due to interest costs associated with cash flow, while rebate advocates contend they will not impose any significant costs on providers. We develop